Challenges And Opportunities As mRNA Manufacturing Spreads Its Wings Beyond COVID-19 Vaccines

17 Aug 2022

In the second part of In Vivo's series on mRNA manufacturing, we look at the technology behind the Moderna and Pfizer/BioNTech COVID-19 vaccines. Experts in the field are working on a variety of improvements that will enable quicker, cheaper, surer development and production of what could turn out to be a wide array of vaccines and therapeutics to be churned out by emerging mRNA platforms.

Butterfly hand — Having emerged, mRNA is now preparing for wider horizons • Source: Shutterstock

Now that new mRNA manufacturing technologies have come seemingly out of nowhere to quickly produce billions of COVID-19 vaccine doses, companies are working to optimize them into robust platform technologies that could produce a whirlwind of innovative drug products now under development.

In a recent discussion on easing bottlenecks to meet the potential of mRNA, an expert panel explored a range...